Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiselimod for mild to moderate ulcerative colitis
2020-005232-30Phase 2Completed
- Sponsor
- Salix Pharmaceuticals, Inc.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amiselimod in autoimmune colitis (3 arms), sponsored by Salix Pharmaceuticals, Inc. Primary endpoint: Change from baseline in modified Mayo score at Day 85. Started Apr 2021; status: completed.
02
Drugs
amiselimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-005232-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005232-30.